JP2008528469A5 - - Google Patents

Download PDF

Info

Publication number
JP2008528469A5
JP2008528469A5 JP2007551744A JP2007551744A JP2008528469A5 JP 2008528469 A5 JP2008528469 A5 JP 2008528469A5 JP 2007551744 A JP2007551744 A JP 2007551744A JP 2007551744 A JP2007551744 A JP 2007551744A JP 2008528469 A5 JP2008528469 A5 JP 2008528469A5
Authority
JP
Japan
Prior art keywords
compound
optionally
combination according
hydrogen
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007551744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008528469A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2006/000206 external-priority patent/WO2006077425A1/en
Publication of JP2008528469A publication Critical patent/JP2008528469A/ja
Publication of JP2008528469A5 publication Critical patent/JP2008528469A5/ja
Withdrawn legal-status Critical Current

Links

JP2007551744A 2005-01-21 2006-01-20 ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤 Withdrawn JP2008528469A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64596305P 2005-01-21 2005-01-21
PCT/GB2006/000206 WO2006077425A1 (en) 2005-01-21 2006-01-20 Combinations of pyrazole kinase inhibitors and further antitumor agents

Publications (2)

Publication Number Publication Date
JP2008528469A JP2008528469A (ja) 2008-07-31
JP2008528469A5 true JP2008528469A5 (https=) 2009-03-12

Family

ID=35966985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007551744A Withdrawn JP2008528469A (ja) 2005-01-21 2006-01-20 ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤

Country Status (11)

Country Link
US (1) US20080161355A1 (https=)
EP (1) EP1845975A1 (https=)
JP (1) JP2008528469A (https=)
KR (1) KR20070107707A (https=)
CN (1) CN101146533A (https=)
AU (1) AU2006207322A1 (https=)
BR (1) BRPI0606319A2 (https=)
CA (1) CA2593475A1 (https=)
MX (1) MX2007008809A (https=)
RU (1) RU2007131101A (https=)
WO (1) WO2006077425A1 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2256106T3 (pl) 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
MX2007008781A (es) * 2005-01-21 2007-09-11 Astex Therapeutics Ltd Compuestos farmaceuticos.
JP5475234B2 (ja) * 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
US20090036607A1 (en) * 2005-03-03 2009-02-05 Mitsubishi Rayon Co., Ltd. Polymer particle, resin composition containing same, and molded body
EP1743890A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
US7897589B2 (en) 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743892A1 (en) 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP2027109A1 (en) * 2006-05-05 2009-02-25 Astex Therapeutics Limited 4- (2, 6-dichloro-benzoylamino) -1h-pyrazole-s-carboxylic acid (1-methanesulph0nyl-piperidin-4-yl) -amide for the treatment of cancer
WO2007129062A1 (en) * 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
WO2008001101A2 (en) * 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
EP2049106A2 (en) * 2006-07-14 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations
EP2049516A2 (en) * 2006-07-14 2009-04-22 Astex Therapeutics Limited Pharmaceutical compounds
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
EP2070916A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft 2-Aryl-thiazol-4-carbonsäureamid-Derivate, deren Herstellung und Verwendung als Arzneimittel
EP2070925A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-substituierte Tiazol-4-carbonsäureamid-Derivative deren Herstellung und Verwendung als Arzneimittel
EP2070924A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel
JP2012504646A (ja) * 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
CN102231983A (zh) * 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
US20100144687A1 (en) 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
EP3406260B1 (en) * 2009-05-13 2020-09-23 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
FR2947546B1 (fr) * 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
HUE032571T2 (en) 2009-10-01 2017-09-28 Janssen Pharmaceutica Nv Proteasome inhibitors for treating cancer
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
EP2640394A4 (en) 2010-11-17 2015-02-25 Univ North Carolina PROTECTION OF KIDNEY TISSUE FROM ISCHEMIA BY THE INHIBITION OF PROLEVERATIVE KINASES CDK4 AND CDK6
EP2935248B1 (en) * 2012-12-21 2018-02-28 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN103012428A (zh) * 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
HK1222766A1 (zh) 2013-03-15 2017-07-14 G1治疗公司 高效的抗赘生剂和抗增生剂
DK2968290T3 (da) 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
BR112016012141A2 (pt) * 2014-01-15 2017-08-08 Novartis Ag "combinações farmacêuticas, uso das mesmas, e embalagem comercial"
WO2015161285A1 (en) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use in the protection of hematopoietic stem and progenitor cells against ionizing radiation
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CA2987552A1 (en) 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors
US10723705B2 (en) 2015-08-14 2020-07-28 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017157873A1 (en) 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
CN109803684B (zh) 2016-08-23 2022-08-23 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
US11083722B2 (en) 2017-03-16 2021-08-10 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of breast cancer
CN107652284B (zh) * 2017-09-30 2020-01-31 武汉九州钰民医药科技有限公司 用于治疗增殖性疾病的cdk抑制剂
CN107686477B (zh) * 2017-09-30 2020-01-31 武汉九州钰民医药科技有限公司 作为cdk4/6抑制剂的新型化合物及其应用
CN115605460A (zh) 2020-04-29 2023-01-13 普莱希科公司（Us） 杂环化合物的合成
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
KR102507397B1 (ko) * 2020-09-10 2023-03-07 계명대학교 산학협력단 히스톤 탈아세틸화효소 억제 활성을 갖는 신규 화합물 및 이의 용도
CN112755023B (zh) * 2021-01-22 2023-04-25 湖南师范大学 一种新型表观遗传因子抑制剂2800z在制备肝癌药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282361A (en) * 1978-03-16 1981-08-04 Massachusetts Institute Of Technology Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines
US5164196A (en) * 1987-05-19 1992-11-17 Ventech Research, Inc. Crotoxin complex as cytotoxic agent
US5002755A (en) * 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
US5514665A (en) * 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
US5502068A (en) * 1995-01-31 1996-03-26 Synphar Laboratories, Inc. Cyclopropylpyrroloindole-oligopeptide anticancer agents
JP2000504014A (ja) * 1996-01-30 2000-04-04 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US20040087798A1 (en) * 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
EP1372631A4 (en) * 2001-02-28 2005-07-27 Brian C Giles METHOD AND FORMULA FOR ANTITUMOR AND ANTIMETASTATIC EFFECT
JPWO2002074298A1 (ja) * 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP1480597A4 (en) * 2001-05-11 2005-02-02 Burnham Inst SCREENING, DIAGNOSTIC AND THERAPY PROCEDURES IN CONNECTION WITH RIZ
ES2251677T3 (es) * 2002-01-22 2006-05-01 Warner-Lambert Company Llc 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas.
WO2003075839A2 (en) * 2002-03-04 2003-09-18 Aton Pharma, Inc. Methods of inducing terminal differentiation
ATE378336T1 (de) * 2002-09-19 2007-11-15 Schering Corp Imidazopyridine als hemmstoffe cyclin abhängiger kinasen
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
PL2256106T3 (pl) * 2003-07-22 2015-08-31 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
JP5475234B2 (ja) * 2005-01-21 2014-04-16 アステックス・セラピューティクス・リミテッド 医薬化合物
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
TW200745003A (en) * 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds

Similar Documents

Publication Publication Date Title
JP2008528469A5 (https=)
JP2008528468A5 (https=)
JP7696443B2 (ja) Ｅｇｆｒ変異を有するがんを処置するためのアミノ置換ヘテロ環類
JP6532878B2 (ja) 組合せ医薬
JP2008528471A5 (https=)
US20230338314A1 (en) Methods for the treatment of myeloid derived suppressor cells related disorders
RU2020112759A (ru) Гетероциклические соединения в качестве ингибиторов PAD
RU2007131101A (ru) Комбинации пиразольных ингибиторов киназы и других средств против злокачественных новообразований
JP2024072291A (ja) 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法
JP2009536620A5 (https=)
JP2007517807A5 (https=)
US9205091B2 (en) Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
JP2005526794A5 (ja) ベンズイミダゾールおよびマイトジェン活性化およびｒｈｏキナーゼ阻害剤としてのその使用
US20240197729A1 (en) ALK-5 Inhibitors and Uses Thereof
BRPI0612076A2 (pt) modulação sinergìstica de flt3 cinase empregando-se moduladores de aminopirimidinas cinase
EP4419094A1 (en) Compositions and methods for treatment of hyperproliferative, inflammatory, and immunological diseases, and infections
WO2025076109A1 (en) Use of elesclomol to treat clear-cell ovarian cancers with mutations in arid1a
US20240360135A1 (en) Imidazo[1,2-b]pyridazinyl compounds and uses thereof
RU2008129623A (ru) Ингибиторы ccr9 активности
CA3209512A1 (en) Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases
EA201000882A1 (ru) Соединение, его применение и фармацевтическая композиция, содержащая это соединение
MA28930B1 (fr) Derives pyridiniques d'indolin-2-one , leur preparation et leur application en therapeutique
JP6737443B2 (ja) 治療的処置でのＢＣＲＰ阻害剤としての使用のための４−アミノ−３−フェニルアミノ−６−フェニルピラゾロ［３，４−ｄ］ピリミジン誘導体
US20210220331A1 (en) Inhibitors of ires-mediated protein synthesis
WO2018222975A1 (en) Methods for the treatment of cancer